IMUX
IMMUNIC, INC.
NASDAQ · Healthcare · Biotechnology · US
$7.78
+2.37%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$7.78
From 52W high−53.96%
Volume108131.00
Market cap$106.15M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataNov 4, 2026
Open
$7.78
From 52W high
−53.96%
Volume
108131.00
Market cap
$106.15M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.4x
P/E (TTM)
—
RSI (14)
43.6
MomentumView details →
1D Return
+2.37%
YTD Return
+43.82%
SummaryUpdated Jun 1, 2026
Immunic, Inc. (NASDAQ:IMUX) is a clinical-stage biopharmaceutical company founded in 2016 and headquartered in New York, New York. The company went public in April 2014 and focuses on developing selective oral immunology therapies for treating chronic inflammatory and autoimmune diseases. Immunic operates as a research-focused organization with no current revenue-generating products, instead investing heavily in clinical trials to advance its pipeline of experimental treatments through various phases of regulatory approval.
Similar companies
Latest newsMore news →
IMMUNIC, INC. announced that it will host a virtual R&D Day focused on progressive multiple sclerosis on November 5, 2026, at 12:30 p.m. ET.6d agoImmunic announced that new clinical, biomarker and preclinical data for vidofludimus calcium are being presented in four posters at the MSToronto2026 meeting.14d agoImmunic announced that four abstracts on clinical, biomarker and preclinical data for investigational vidofludimus calcium were accepted for presentation at MSToronto2026.28d ago